ZOMETA® - Reduces SREs From Bone Metastases In Lung Cancer Patients

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

About ZOMETA: defend against SREs across a broad range of tumour types

About ZOMETA
Lung Cancer
ZOMETA reduces SREs

ZOMETA^® effectively helps to protect patients with lung cancer
from the threat of SREs

Time to first SRE,* ZOMETA vs placebo in patients with advanced lung cancer and other solid tumours⁶

*Excludes hypercalcemia of malignancy.

ZOMETA significantly delayed SREs vs placebo by more than 2 months (P=.023)⁶
ZOMETA reduced the risk of SREs vs placebo by 27% (P=NS)⁶

ZOMETA can delay and reduce SREs in patients with bone metastases from lung cancer and other solid tumours⁶

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

ZOMETA® effectively helps to protect patients with lung cancer from the threat of SREs

ZOMETA can delay and reduce SREs in patients with bone metastases from lung cancer and other solid tumours6

ZOMETA^® effectively helps to protect patients with lung cancer
from the threat of SREs

ZOMETA can delay and reduce SREs in patients with bone metastases from lung cancer and other solid tumours⁶